Zerumbet ginger extract (ZGE) shows strong anticancer potential and enhances doxorubicin (DOX) efficacy against breast cancer while reducing its systemic toxicity. GC–MS identified zerumbone as a key bioactive. ZGE inhibited 4 T1 cell growth and tumor progression in mice and improved antioxidant activity. Combined ZGE + DOX treatment boosted antitumor effects and alleviated DOX‐induced cardiotoxicity, hepatotoxicity, and nephrotoxicity, as reflected in biochemical markers. Mechanistically, ZGE suppressed TRPM2 and calcium signaling, promoting ROS‐mediated apoptosis. These findings support ZGE as a promising adjuvant in breast cancer therapy.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: